A combination of protective antigens of mycobacterium tuberculosis and use thereof
By constructing a fusion protein containing antigens such as Ag85B, Rv2465c, Rv2029c, and Rv3406, a recombinant subunit and nucleic acid vaccine was prepared, which solved the shortcomings of existing vaccines in preventing tuberculosis and latent infection in adolescents and adults, and achieved a more efficient immune protection effect.
Patent Information
- Application Number
- CN202411754205.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-29
- Publication Date
- 2026-05-29
AI Technical Summary
Existing tuberculosis vaccines, such as BCG, are not effective in preventing pulmonary tuberculosis in adolescents and adults, and cannot inhibit the reactivation of latent tuberculosis infection. Existing candidate vaccines have insufficient protective efficacy in clinical trials, and there is a need to develop new vaccines that can elicit a more effective protective response.
A fusion protein containing antigens such as Ag85B, Rv2465c, Rv2029c, and Rv3406 was constructed and linked via a P2A linker to prepare recombinant subunit vaccines and nucleic acid vaccines. The proteins were expressed using a chimpanzee adenovirus vector, and the immunoprotective efficacy was verified using a mouse model.
It significantly improved the immunoprotective efficacy against Mycobacterium tuberculosis in mouse models, especially during the latent and acute infection stages, enhancing the immune response and reducing bacterial load.
Smart Images
Figure CN122097559A_ABST